期刊
PROTEOMICS CLINICAL APPLICATIONS
卷 3, 期 7, 页码 853-861出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.200800141
关键词
Angiopoietin-like protein 3; Matrix metalloproteinase-9; MS; Ovarian cancer; Serum depletion
资金
- Ministry of Science and Technology, China [2006AA02Z4A2, 2006AA02A303, 2007DFC30360, 2008DFA11320, 2006DFA2950]
- National Center for Integrative Biomedical Informatics from NIH, USA [U54DA021519]
- NIH, USA [R21CA106949-01A1]
- Ovarian Cancer Working Group Grant from the Cancer Research Institute
Epithelial ovarian cancer (EOC) ranks fifth as a cause of cancer deaths in women. Current diagnostic and monitoring markers have limited reliability for the detection of disease. We have tested the possibility of identifying candidate biomarkers present at low nanogram to picogram levels after removing both the 12 most abundant and 77 moderately abundant proteins from serum samples of EOC patients using antibody affinity columns. We showed that this approach allows the identification, of proteins that are expressed at nanogram per liter levels in the serum. Using ICAT/MS/MS analysis, we identified 51 proteins that are differentially expressed by at least twofold. These proteins include leucine-rich alpha-2-glycoprotein, matrix metalloproteinase-9 (MMP-9), inter-alpha-trypsin inhibitor heavy chain H1, insulin-like growth factor-binding protein 6, insulin-like growth factor-binding protein 3, isoform 1 of epidermal growth factor receptor, angiopoictin-like protein 3 (ANGPTL3) and phosphatidylcholine-sterol acyltransferase. We confirmed the differential expression of MMP9 and ANGPTL3 in normal and ovarian cancer sera by ELISA assays. Further robust clinical evaluation of the candidate markers identified is necessary.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据